Myriad Genetics, Inc.
MYGN today announced it has obtained an exclusive license to
intellectual property covering the analysis of the RAD51C gene for risk of
hereditary breast and ovarian cancer. In several studies, mutations in the
RAD51C gene have been identified and associated with an increased risk for
hereditary breast and ovarian cancer.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in